2020 Outlook: Innovation or Status Quo?
Thursday, January 30th | 1:30 pm Eastern
Register Me Now!
Will 2020 bring innovation or more of the same for employers? This presentation explores how formulary changes, biosimilars, gene therapies, public policy and PBM contracting will contribute to employer strategies moving forward.
Attendees will learn:
• How employers can better evaluate the PBM marketplace and what impact common contract caveats have on total cost
• How biosimilars and gene therapies will impact employer specialty spend
• What other market dynamics, including new formularies, pricing models and public policy factor into employer strategies
Mike Stull, MBA
Chief Strategy Officer
Matt Harman, PharmD
Director of Pharmacy